Texas Rare Alliance

TX Rare is dedicated to improving access and health outcomes for nearly 3 million Texas #raredisease patients through education and advocacy.

[Texas Rare Alliance @txrare]

Our Founder & President,
@khrystalkdavis
took a strong position against PBMs in her op-ed calling for reform. Since PBMs emerged, patients face increasing barriers to access and pay more out of pocket for the medications they need. https://t.co/3m3bqiRFzY

[Texas Rare Alliance @txrare]

Learn how the #PBM business model is misaligned between the interests of the #PBMs and the stakeholders they claim to serve. https://t.co/pIhHIitF7c

[Texas Rare Alliance @txrare]

There is an alarming shortage of some injectable drugs for #cancer and other life-threatening diseases, the result of misdirected government policies. It’s time for #340B reform. Put patients first. https://t.co/KgBzUyoJu5

[Texas Rare Alliance @txrare]

“Earlier this month, Grassley told Reuters the #PBM system was ‘an opaque operation. Transparency brings accountability, and there’s no accountability.’” https://t.co/rgsgUmAKuB

[Texas Rare Alliance @txrare]

Patient advocates are sharing their concerns with Congress on how the #340B program needs to be reformed. https://t.co/igf67W7Btb

[Texas Rare Alliance @txrare]

Tx faces significant lost therapies, innovation and 54,000+ #biopharma jobs under drug #pricecontrols bill from @RepRichardNeal @FrankPallone @repdavidscott. Bill would hurt patient access & care. More at: https://t.co/oCrwB1v8yV.

[Texas Rare Alliance @txrare]

A group of US Senators is seeking information about how the #340B program can be reformed. More here: https://t.co/7SRWffUHHv

[Texas Rare Alliance @txrare]

#PBM compensation and the list price of a medicine create an incentive for #PBMs to prefer higher list prices. Delinking this compensation arrangement could save an estimated $39.9 billion over a 10-year period. https://t.co/3ffiSSYyj8

[Texas Rare Alliance @txrare]

A big thank you to our own Senator @JohnCornyn for joining with the 24 cosponsors of the #MCED Screening Coverage Act to create a pathway for early cancer detection for Texans on Medicare.

[Texas Rare Alliance @txrare]

@JohnCornyn has joined 24 of his colleagues in cosponsoring the Medicare #MCED Screening Coverage Act, which will ensure America’s seniors will have timely access to early detection technologies. Thank you, Sen. Cornyn!

[Texas Rare Alliance @txrare]

Patients should benefit from negotiated drug discounts. Right now, only #PBMs benefit – and this overcharging must stop. We urge @WaysMeansCmte @WaysandMeansGOP to fix this. Help patients save at the pharmacy counter with this #PBMreform.

[Texas Rare Alliance @txrare]

Lean how the #340B program is potentially and unnecessarily encouraging the purchase of higher-priced prescription meds, which may inflate costs for patients. https://t.co/Ad71YVog62

[Texas Rare Alliance @txrare]

@JohnCornyn has joined 24 of his colleagues in cosponsoring the Medicare #MCED Screening Coverage Act, which will ensure America’s seniors will have timely access to early detection technologies. Thank you, Sen. Cornyn!

[Texas Rare Alliance @txrare]

Drug discounts that benefit only #PBMs should be shared with patients. We hope this important #PBMreform is top of mind for @SenFinance members as they discuss #PBM accountability and PBM overcharging of patients. Thank you, Sen. @JohnCornyn for your attention to this issue.

[Texas Rare Alliance @txrare]

Drug discounts that benefit only #PBMs should be shared with patients. We hope this important #PBMreform is top of mind for @SenFinance members as they discuss #PBM accountability and PBM overcharging of patients. Thank you, Sen. @JohnCronyn for your attention to this issue.

[Texas Rare Alliance @txrare]

Stay up to date on the dozens of #PBM bills Congress is considering regarding #drugpricing and #PBMreform. https://t.co/RKmST97z30

[Texas Rare Alliance @txrare]

Learn why congressional oversight of the troubled #340B program is needed in order to help vulnerable patients. https://t.co/J4s4OpJqbR

[Texas Rare Alliance @txrare]

A bipartisan US Senate #340B working group wants to ensure the program is functioning as it should. https://t.co/5qg1m7hwUH

[Texas Rare Alliance @txrare]

De-linking the compensation of #PBMs from a drug’s price is key to meaningful #PBMreform. Learn more here about the #PBMAct, which seeks to do just this. https://t.co/hx4wiESbcK

[Texas Rare Alliance @txrare]

Learn about the misaligned incentives regarding the role of #PBMs, the massive corporate middlemen in the drug supply chain. “Incentives” = profit-making opportunities for the largest PBMs. https://t.co/xVVJCunpo6

[Texas Rare Alliance @txrare]

.@VitalTransform study shows #GovernmentMandatedDrugPrices would result in 68% reduction in new FDA-approved medicines. Over 10 years, that equals 237 new therapies never making it to market. https://t.co/DEJ2DlOoY5